NASDAQ:ANIP • US00182C1036
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ANI PHARMACEUTICALS INC (ANIP).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-16 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-10 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-09 | Truist Securities | Maintains | Hold -> Hold |
| 2025-09-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-08 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-11 | Truist Securities | Maintains | Hold -> Hold |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-10 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-21 | Truist Securities | Maintains | Hold -> Hold |
| 2025-04-11 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-14 | Jefferies | Initiate | Buy |
| 2025-03-12 | JP Morgan | Initiate | Overweight |
| 2025-03-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | Leerink Partners | Initiate | Outperform |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-22 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-11 | Piper Sandler | Initiate | Overweight |
| 2024-09-18 | Raymond James | Maintains | Outperform -> Outperform |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-11 | Truist Securities | Downgrade | Buy -> Hold |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 486.816M 53.86% | 614.376M 26.20% | 883.366M 43.78% | 1.087B 23.05% | 1.24B 14.08% | 1.355B 9.27% | 1.402B 3.47% | 1.525B 8.77% | 1.508B -1.11% | 1.547B 2.59% | 1.586B 2.52% | |
| EBITDA YoY % growth | 107.894M 257.86% | 82.968M -23.10% | 205.759M 148.00% | 272.58M 32.48% | 332.47M 21.97% | 360.19M 8.34% | 417.95M 16.04% | 502.86M 20.32% | N/A | N/A | N/A | |
| EBIT YoY % growth | 48.103M 263.06% | 15.237M -68.32% | 114.342M 650.42% | 287.64M 151.56% | 343.66M 19.48% | 389.91M 13.46% | 177.07M -54.59% | 214M 20.86% | N/A | N/A | N/A | |
| Operating Margin | 9.88% | 2.48% | 12.94% | 26.46% | 27.71% | 28.78% | 12.63% | 14.03% | N/A | N/A | N/A | |
| EPS YoY % growth | 4.72 234.75% | 5.20 10.17% | 7.87 51.35% | 9.09 15.55% | 10.82 19.00% | 11.78 8.81% | 12.94 9.90% | 13.72 5.98% | 14.05 2.40% | 14.24 1.38% | 14.40 1.15% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.48 -12.80% | 2.22 23.36% | 2.54 24.60% | 2.97 27.60% | 1.85 24.77% | 2.54 14.38% | 2.90 14.10% | 3.38 13.56% |
| Revenue Q2Q % growth | 217.87M 10.53% | 268.57M 27.06% | 295.78M 29.83% | 330.09M 33.61% | 267.34M 22.71% | 291.62M 8.58% | 288.56M -2.44% | 314.87M -4.61% |
| EBITDA Q2Q % growth | 49.476M 0.80% | 68.645M 13.91% | 78.629M -26.17% | 91.68M -27.68% | 68.136M 37.72% | 81.702M 19.02% | 82.824M 5.34% | 100.78M 9.93% |
| EBIT Q2Q % growth | 43.627M 66.55% | 67.693M 380.36% | 81.675M 116.63% | 95.594M 170.39% | N/A | N/A | N/A | N/A |
All data in USD
14 analysts have analysed ANIP and the average price target is 112.2 USD. This implies a price increase of 54.08% is expected in the next year compared to the current price of 72.82.
ANI PHARMACEUTICALS INC (ANIP) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of ANI PHARMACEUTICALS INC (ANIP) is 1.48 USD and the consensus revenue estimate is 217.87M USD.
The consensus rating for ANI PHARMACEUTICALS INC (ANIP) is 84.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.